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Abstract
Background: The presence of microalbuminuria can be associated with overt nephropathy and cardiovascular
disease in patients with type 1 diabetes (T1D). We aimed to determine the incidence and evaluate the baseline
predictors for the development of microalbuminuria in patients with T1D.
Methods: This study is a longitudinal cohort study of 122 normoalbuminuric patients with T1D who were
receiving routine clinical care at baseline. A detailed medical history was taken, and a physical examination was
performed at baseline. All of the patients were regularly examined for diabetes-associated complications. An
analysis of predictors was performed using the Cox regression.
Results: Over 6.81 (3.59-9.75) years of follow-up, 50 (41%) of the patients developed microalbuminuria. The
incidence density was 6.79/100 people per year (95% CI 5.04-8.95), and the microalbuminuria developed after 5.9
(2.44-7.76) and 11 (5-15) years of follow-up and diabetes duration, respectively. After an individual Cox regression,
the baseline variables associated with the development of microalbuminuria were age, age at diagnosis, duration
of diabetes, systolic and diastolic blood pressure, fasting glycemia, body mass index (BMI), total cholesterol and
triglycerides levels, cholesterol/HDL ratio and a family history of type 2 diabetes.After a multivariate Cox regression,
the only independent factors associated with the development of microalbuminuria were BMI [HR 1.12 (1.03-1.21)]
and cholesterol/HDL ratio [HR 1.32 (1.05-1.67)].
Conclusions: A higher BMI and cholesterol/HDL ratio increased the risk of developing microalbuminuria in young
patients with T1D after a short follow-up. Both risk factors are modifiable and should be identified early and
followed closely.
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Background
Type 1 diabetes (T1D) leads to an increased risk of
morbidity and early mortality due to chronic complica-
tions [1] affecting both the micro- and macro-
vasculature.
Diabetic nephropathy (DN) is one of the most serious
chronic complications of T1D, affecting approximately
20-30% of patients and increasing the risk of cardiovas-
cular disease [2] and end-stage renal disease [3].
Diabetic nephropathy consists of several stages. Early
microalbuminuria is considered to be one of its most
important predictors [4] and is also associated with the
development of cardiovascular disease [5]. Furthermore,
the progressive decline of renal function in patients with
T1D is an early event that occurs in a large proportion
of patients with microalbuminuria [6]. Metabolic and
hemodynamic factors contribute to the development of
diabetic nephropathy, probably by interacting with a
genetic susceptibility [7,8].
The aim of this longitudinal study was to determine
the incidence of and predictors for the development of
microalbuminuria in a sub-set of Brazilian patients with
T1D.
Methods
We conducted a longitudinal observational study includ-
ing outpatients with T1D who regularly attended the
diabetes clinic at the University Hospital Pedro Ernesto,
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de Janeiro, Brazil. The inclusion criteria were a T1D
diagnosis, regular follow-up at our clinic and agreement
to participate by means of informed consent. Exclusion
criteria were less than 2 follow-up visits, the presence of
either incipient or clinical nephropathy at baseline and
end-stage renal disease. The initial cohort started in Janu-
ary 1991 when 110 patients were invited to participate in
a study of the complications of diabetes. Initially, 50
patients were enrolled in the protocol, and these data
were published elsewhere [9]. A dynamic cohort analysis
was then performed. During the follow-up, the patients
were seen in our clinic and received routine clinical care.
All of the patients were regularly examined for com-
plications of diabetes. At baseline, detailed medical his-
tories were taken, and physical examinations were
performed. The data of interest included gender, age,
age at diagnosis of diabetes, first-degree family history
of type 2 diabetes (T2D), duration of the disease and
daily insulin dose. All of the participants provided three
accurately overnight urine samples with an interval of at
least one week between collections within a period of
six months. The participants were instructed to collect
urine under their usual conditions, avoiding intensive
physical activity. The urine was collected into containers
without preservatives. The urinary volume was recorded,
and the aliquots were stored in glass tubes at -20°C
until analysis (within 2 months). Urinary albumin con-
centration was estimated using a solid-phase competitive
chemiluminescent enzyme immunoassay (Immulite 1000
Systems, DPC Medlab, Los Angeles, CA, sensitivity of
0.9 μg/ml) with intra-assay and inter-assay coefficients
of variation of 2.4% and 5.7%, respectively. The patients
with albumin excretion rates (AER) of < 20 μg/min dur-
ing the follow-up were classified as normoalbuminuric.
Microalbuminuria was defined as an AER of ≥ 20 and <
200 μg/min in at least two out of three of the overnight
urine specimens collected.
Each urine specimen was tested for the presence of
urinary infections and if present, the urine was dis-
carded, and a new sample was collected after treatment.
Normal serum creatinine levels (0.8-1.4 mg/dl) and nor-
mal urinary sediments (absence of proteins, red blood
cells, hemoglobin, white blood cells, nitrites and casts)
were used to exclude primary renal disease.
Fasting blood samples were obtained on the same day
as the overnight urine delivery. All of the patients were
given their usual insulin doses after the fasting blood
collection. Blood was collected two hours after the
patients’ usual breakfast for the assessment of postpran-
dial glycemia.
Triglyceride, total cholesterol, high-density lipoprotein
(HDL) cholesterol, fasting plasma glucose (FPG) and
plasma creatinine levels were measured by an enzymatic
procedure using an auto analyzer (Cobas - Mira Roche).
Low-density lipoprotein (LDL) cholesterol levels were
calculated using the Friedwald method[10]. Glycated
hemoglobin (A 1c) levels were determined by HPLC
(Hitachi L-9100) with reference range of 2.6% to 6.2%.
An ophthalmologist examined all of the retinas by fun-
doscopy through dilated pupils using slit lamp stereo-
scopic biomicroscopy, and the patients were classified
into two groups depending on the presence or absence of
either nonproliferative or proliferative retinopathy. The
more severely affected eye was used for the evaluation.
Blood pressure was measured 3 times after 5 minutes
of rest in the supine position by the same observer
using a standard mercury sphygmomanometer. The
mean of these values was then calculated. Weight and
height were measured to the nearest 0.1 Kg and 0.1 cm,
respectively. Body mass index (BMI-Kg/m
2)w a sc a l c u -
lated, and the patients were classified into two groups
(normal, BMI < 25 kg/m
2 for adults and < 85
th percen-
tile for children and adolescents or overweight/obese,
when higher values were obtained) [11].
The observational design was approved by the local
ethics committee.
Numeric values are expressed as medians (interquar-
tile ranges), and categorical variables are expressed as
counts (percentages). The analysis was performed using
the statistical package Stata version 10 software. Cox
regression univariate analysis was performed on each
baseline variable. The patients contributed until they
developed microalbuminuria, and the outcome was
defined as the time elapsed until the development of
microalbuminuria. Cox’s proportional hazards model
was used to estimate the hazard ratios and 95% confi-
dence intervals. The variables were eligible to enter the
multivariate model if the p < 0.25 in univariate Cox
regression. The proportional hazards assumption was
verified by analysis of the Schoenfeld residuals and
assessment of a graph of the survival function versus the
survival time. The incidence rate of microalbuminuria is
expressed as cases/100 patients/year. Receiver operating
characteristic (ROC) analysis was performed to identify
the threshold value of the baseline AER that predicted
the development of microalbuminuria.
Results
The baseline clinical data for all of the patients in the
cohort analysis is presented in Table 1.
Over the 6.81 (3.59-9.75) years of follow-up, 50 (41%)
of the 122 normoalbuminuric patients at baseline ful-
filled the criteria for microalbuminuria. This yielded
an incidence density of 6.79/100 people/year (95% CI,
5.04-8.95).
The follow-up period and the duration of diabetes
until the development of microalbuminuria were 5.9
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AERs were 32.3 (22-50) ụg/min and 7.35 (4.95-11.6) ụg/
min for patients who had microalbuminuria and patients
who had persistent normoalbuminuric,respectively.
The baseline AER did not significantly predict the
development of microalbuminuria in the ROC analysis
(AUC = 0.57, 95% CI 0.46-0.67), and there was no single
best threshold value.
The baseline variables that were selected to enter the
multivariate proportional hazards regression were age, age
at diagnosis, duration of diabetes, systolic blood pressure
(sBP), diastolic blood pressure (dBP), FPG, BMI, total cho-
lesterol and triglycerides levels, cholesterol/HDL and LDL/
HDL ratio and a family history of T2D.(Table 2).
After multivariate Cox regression, the independent
factors that were associated with the development of
microalbuminuria were BMI and cholesterol/HDL ratio
(Table 2).
Discussion
In our prospective study of normoalbuminuric patients
with juvenile-onset T1D, 41% developed microalbumi-
nuria after an 11-year duration of diabetes and 5.9 (2.44-
7.76) years of follow-up, resulting in a greater overall
crude incidence and incidence density of microalbumi-
nuria than those reported in other studies [2,12-17].
In addition to the most described predictors of the
progression to diabetic nephropathy and AER levels in
T1D, such as duration of diabetes [11,18,19], blood pres-
sure [11,18,19] and lipid levels [18-20], the development
of microalbuminuria in our population was determined
by age, age at diagnosis, BMI, FPG and a family history
of T2D.As previously reported[21,22],A1c did not pre-
dict the development of microalbuminuria in our popu-
lation,which is in contrast to other reports[12-14,18,19].
In our study, the levels of AER at baseline also did not
predict the development of microalbuminuria, which is
in contrast to other studies where higher initial levels of
AER predicted the progression to microalbuminuria
[13,14].
In addition to the classical risk factors, others may
influence the development of microalbuminuria [23].
Considering the increasing frequency of weight gain and
obesity in patients with T1D over the last decade, these
clinical conditions that result in insulin resistance may
be involved in the pathology of microalbuminuria [24].
Table 1 Baseline characteristics of the patients with type 1 diabetes
Total Microalbuminuric group Normoalbuminuric group
N 122 50 72
Gender (Male) 59(48.4) 21 (42.0) 38 (52,8)
Age (years) 17 (12.0-25.2) 20 (14-26) 14 (9-21)
Age at diagnosis (years) 12 (7.0-9.0) 14 (9-23) 11 (6-18)
Duration of diabetes (years) 3 (1.0-5.6) 4.0 (2.0-8.3) 2.0 (1.0-4.5)
Insulin dose (IU/Kg/day) 0.7 (0.46-0.99) 0.73 (0.59-1.12) 0.63 (0.44-0.98)
Systolic blood pressure (mmHg) 103 (97-110) 103 (100-110) 104 (97-110)
Diastolic blood pressure (mmHg) 68 (60-73) 69 (61-73) 68 (60-73)
Fasting plasma glycemia (mg/dl) 150 (110-233) 163 (123-253) 147 (108-224)
Two-hour post-prandial glycemia (mg/dl) 221 (148-312) 229 (148-345) 214 (149-306)
A1c (%) 7.2 (6.5-8.11) 7.0 (6.5-7.9) 7.3 (6.6-8.5)
Total cholesterol level (mg/dl) 158 (140-191) 164 (143-197) 157 (138-183)
Trygliceride level (mg/dl) 60 (46-81) 68 (50-97) 55 (44-73)
HDL cholesterol level (mg/dl) 49 (41-57) 49 (42-56) 48 (39-63)
LDL cholesterol level (mg/dl) 105 (86-137) 113 (92-14) 101 (83-121)
Cholesterol/HDL ratio 3.3 (2.7-4.1) 3.4 (2.8-4.2) 3.2 (2.6-4.0)
LDL/HDL ratio 2.3 (1.6-3.1) 2.5 (1.8-3.4) 2.0 (1.5-2.9)
Plasma creatinine level (mg/dl) 0.65(0.6-0.8) 0.7 (0.6-0.9) 0.6 (0.6-0.8)
Albumin excretion rate (μg/min) 7.0 (4.3-10.2) 7.4 (5.1-11.5) 6.8 (4.1-10.0)
BMI (kg/m
2) 20 (18-22) 20.7 (18.9 22.7) 19.2 (17.1-21)
Overweight or obese 22 (18) 8 (16.0) 14 (19.4)
Presence of retinopathy * 6(5) 2 (4.1) 4 (5.6)
Family history of type 2 diabetes** 24(22) 13 (28,3) 11 (16,4)
Continuous variables are presented as median (interquartile range), and categorical variables are presented as n (%).A1c, glycated hemoglobin; BMI, body mass
index; HDL, high density lipoprotein; LDL, low density lipoprotein * 2 evaluations are missing ** Data from 8 subjects are missing
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normal weight, the only independent factors associated
with the development of microalbuminuria were BMI
and the cholesterol/HDL ratio.
Intensive insulin treatment, although beneficial for
decreasing the risk of diabetic complications, can result
in weight gain [25]. The effects of weight gain may be
intensified when not accompanied by good glycemic
control. It has been postulated that a first-degree family
history of T2D, already reported to be higher in Brazi-
lian patients with T1D compared to non-diabetic
patients [26], predisposes these patients to a higher risk
of weight gain and insulin resistance.
The features of metabolic syndrome that are asso-
ciated with insulin resistance, which tend to increase
with disease progression [27], were found to be risk fac-
tors for overt nephropathy and renal injury
[13,14,28-31], due in part to low-grade inflammation
and oxidative stress [32]. Patients with T1D can be
more susceptible to LDL oxidation in vitro [33] and
have higher levels of acute-phase proteins compared to
non-diabetic subjects [34].
Higher levels of HDL were found to have a protective
effect against the development of albuminuria in long-
standing type 1 diabetic patients [35]. However, even
when they had normal or slightly high plasma HDL
cholesterol levels, type 1 diabetic patients were predis-
posed to the early development of atherosclerosis
because of the loss of the ability of HDL to protect
arteries from the inhibition of the endothelium-depen-
dent relaxation induced by oxidized-LDL [36]. Total
cholesterol [14] and LDL-cholesterol [13,20] levels were
also associated with the progression to
microalbuminuria.
DN is also associated with cardiovascular disease [37],
and dyslipidemia is considered a risk factor for both
conditions [38]. In addition, cholesterol levels increase
as DN progresses and also correlate positively with the
rate of fall in the glomerular filtration rate[39].
It should be noted that we can intervene to mitigate
many of these factors. However, the effects of these
interventions in affording or delaying the onset of renal
injury in these patients must be addressed. Furthermore,
microalbuminuria reverts without specific treatment in a
significant percentage of patients[40].
These facts are of great importance in deciding the
proper time to initiate a specific treatment, particularly
because most of the patients are young people of repro-
ductive age.
The limitations of our study include the variable fol-
low-up time and the high number of events. In fact, the
final AER levels in those patients who progressed to
Table 2 Cox proportional hazard model of baseline risk factors for development of microalbuminuria in 122 patients
with type 1 diabetes who were followed for seven years
Baseline Data Univariate Analysis Hazard Ratio (95% CI) p value Multivariate Model Hazard ratio (95% CI) p value
Age 1.03 (1.00-1.06) 0.026
Age at diagnosis 1.03 (0.99-1.06) 0.123
Gender 0.92 (0.52-1.63) 0.779
Duration of diabetes 1.03 (0.98-1.07) 0.247
Insulin dose 1.34 (0.77-2.32) 0.302
AER 1.01 (0.96-1.07) 0.660
Systolic blood pressure 1.02 (0.99-1.04) 0.170
Diastolic blood pressure 1.02 (0.99-1.06) 0.210
A1c 1.02 (0.87-1.20) 0.810
Two-hour post-prandial glycemia 0.99 (0.99-1.00) 0.294
Fasting glycemia 1.00(0.99-1.01) 0.234
BMI 1.12 (1.03-1.22) 0.006 1.12 (1.03-1.21) 0.01
Total cholesterol level 1.01 (1.0-1.01) 0.042
HDL cholesterol level 0.99 (0.98-1.02) 0.930
Triglyceride level 1.00 (0.99-1.01) 0.08
LDL cholesterol level 1.01 (1.00-1.01) 0.045
Cholesterol/HDL ratio 1.32 (1.07-1.63) 0.010 1.32 (1.05-1.67) 0.019
LDL/HDL ratio 1.26 (0.97-1.62) 0.079
Presence of retinopathy 1.37 (0.33-5.68) 0.667
Family history of type 2 diabetes 2.03 (1.06-3.92) 0.044
BMI, body mass index; AER, albumin excretion rate; A1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein
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albuminuria, and this group may have included those
patients who spontaneously revert to normoalbuminuria.
Family history of hypertension was absent and ethnicity
was difficult to characterize in the study population
based on ectoscopy or self-report [41], so these data
could not be evaluated as risk factors.
Conclusions
Higher BMIs and cholesterol/HDL ratios at a young age
increased the risk of developing microalbuminuria in
patients with juvenile-onset T1D after a short follow-up.
Both risk factors are modifiable and should be identified
early. We suggest that weight and lipid profiles must be
followed closely in patients with T1D.
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